You are here: Industry Insights > oncology

News List

Future Prospects of Small Molecule and Monoclonal Antibody Drugs in Oncology and Immunology Krebs Qin
October 18, 2024
Specifically, there is a balance between small molecules and monoclonal antibody drugs (mAbs) in the realm of oncology super blockbuster drugs, while immunology appears dominated by monoclonal antibodies and protein-based treatments.
Immuno-Oncology: Current Market Landscape and Future Trends（1） Neeta Ratanghayra
September 18, 2024
Immune Checkpoint Inhibitors & Challenges and Future Directions.
10 Studies on InnoCare’s Oncology Pipelines Selected at the Upcoming 65th Annual Meeting of ASH PharmaSources
November 15, 2023
InnoCare Pharma,announced today that 10 studies from InnoCare's oncology pipeline were selected for presentation at the 65th American Society of Hematology (ASH) Annual Meeting on December 9-12, 2023 in San Diego, California, United States.
A Review of Oncology Biosimilars Products and Companies David Orchard-Webb
May 12, 2022
Biologics and biosimilars are large and generally complex therapeutics produced from living organisms.
A Glimpse of the Oncology Drug Treatment Market in China PharmaSources/Xiaoyaowan
May 31, 2021
According to statistics, the market size of China’s oncology treatment industry reached RMB387.6 billion in 2020, with a compound annual growth rate of 10.3% in the past five years as compared to RMB261.4 billion in 2016, and this market size is expected
Advancing oncology Sarah Harding
March 18, 2021
With so much going on last year, you might be forgiven if you missed a ground-breaking announcement in November 2020 about the ‘Galleri blood test’.
The tumor disappears after infection with coronavirus! Looking at the “killing cancer with the virus” concept in the oncology field PharmaSources/Wang Hong
January 21, 2021
The world is full of wonders. According to an article published by a British doctor in the British Journal of Haematology two days ago, a malignant lymphoma patient’s tumor almost disappeared after infection with coronavirus!
The New NRDL Becomes Official: Many New Oncology Drugs Are Listed and Some Immune Drugs Become Affordable PharmaSources/Xiaobin
January 07, 2021
The National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2020) (“NRDL”) of China was released by the NHSA and Ministry of Human Resources and Social Security of China.
A Comparison of Top Ten Best-Selling Oncology Drugs in China and the U.S. in 2019 PharmaSources/Caicai
December 24, 2020
Information on the top ten best-selling oncology drugs in China and the U.S. in 2019 has recently been released by a related consulting agency of the industry.
Insights Into the Oncology Landscape in China Neeta Ratanghayra
December 24, 2020
Significant increases in incidence rates have made cancer a high priority in China. Despite major government reforms to reduce cancer burdens, problems remain. To fulfill its agenda in cancer innovation, China is embracing new frontiers and opportunities.